A State of Stemness: What if ...?

As researchers track the signals that lure stem cells along apparent developmental detours, it is beginning to look like the cells' plasticity is a natural response to injury. At first, the stem cells seemed to breach the boundaries set in the early embryo, morphing from mesoderm to endoderm, ectoderm to mesoderm, and variations on that theme. This transdifferentiation was originally thought to be a rarity, but cases have accumulated and a new view is emerging: What if everything can turn int

Written byRicki Lewis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

As researchers track the signals that lure stem cells along apparent developmental detours, it is beginning to look like the cells' plasticity is a natural response to injury. At first, the stem cells seemed to breach the boundaries set in the early embryo, morphing from mesoderm to endoderm, ectoderm to mesoderm, and variations on that theme. This transdifferentiation was originally thought to be a rarity, but cases have accumulated and a new view is emerging: What if everything can turn into everything?

Transdifferentiation is the culmination of a highly coordinated response to signals--involving sensing, trafficking, and sometimes cell fusion--that plays out against a backdrop of gene expression possibilities. "There are specific biological conditions under which stem cell plasticity occurs. We don't yet know the molecular cues, but we think that local tissue environment is key," says Richard Mulligan, professor of genetics at Harvard Medical School.

Mulligan's group recently identified 216 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies